

JC08 Rec'd PCT/PTO 0 8 MAY 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
Jacques Mallet, et al

Examiner: Not yet assigned

Art Unit: Not yet assigned

Serial No.: Not yet assigned

Filed: **Herewith**Title: **NOVEL SYSTEM FOR REGULATING
TRANSGENE EXPRESSION**I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231, on5-8-01
Date of DepositSignature *Manuel Mendez***EL685154823US**

Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**


Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Docket No. ST98036 US PCT